견적문의

VILLEJUIF, FRANCE--( / )--Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.

The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Leon Berard (France) (Pierre Saintigny), Segal Cancer Centre, McGill University (Canada) (Wilson H. Miller), UT MD Anderson Cancer Center (USA) (Jordi Rodon and Apostolia-Maria Tsimberidou) and University of California San Diego, Moores Cancer Center (USA) (Razelle Kurzrock), aimed to expand precision oncology to patients with advanced solid tumors that progressed after treatment with standard therapies.

For the first time in the clinic, the WINTHER trial applied transcriptomics (RNA expression testing) to tailor precision medicine in oncology to a greater number of patients based on the increased expression of RNA in tumors compared to normal tissues.

303 patients were enrolled in WINTHER; 107 of whom were ultimately treated according to recommendations made by a committee of cancer experts spanning five countries. These patients had been heavily pretreated, with one quarter having received five or more prior lines of therapy. Of the 107 patients treated, 69 received treatment based on DNA mutation profiling, and 38 based on RNA profiling. Overall, the WINTHER trial succeeded in matching personalized therapy to 35% of patients with advanced cancer.

“The strategy employed in WINTHER resulted in a higher proportion of patients treated than in many precision medicine trials. Previous studies have identified potential treatments for between 5% and 25 % of patients based on DNA profiling alone, our findings represent an important step toward delivering on the true promise of precision medicine in oncology,” said Richard L. Schilsky, Chairman WIN Consortium and Chief Medical Officer of ASCO.

In this trial, patients were first evaluated for targetable alterations in cancer driver genes. Those who were not matched to drugs based on DNA alterations received a treatment tailored to the differences in gene expression between patients’ tumors and normal tissues which were assessed using a patented algorithm developed by the WIN Consortium. Comparisons with normal tissues proved essential due to highly variable RNA expression between patients and across normal tissue types. The WINTHER researchers showed that RNA expression can be used to expand personalized therapy options for patients and that normal tissue biopsy is safe and accepted by patients.

Patients who received therapy optimally tailored to their respective DNA alterations, or consistent with the algorithm recommendation for RNA guided treatment, responded better. Patients with a good performance status and a high degree of matching had a significantly longer median overall survival of 25.8 months versus 4.5 months for others. There was also a correlation between degree of matching and progression-free survival independent of the number of prior therapies. “Importantly, our results show that patients treated with a drug or regimen more closely matched to the molecular profile of their tumor, do better,” observed Razelle Kurzrock, co-leader of the WINTHER trial and Director of UCSD Moores Center for Personalized Cancer Therapy.

“Assessing RNA is an important adjunct to DNA profiling for determining precision treatments. WINTHER rings in a new era for personalized medicine in oncology,” concluded Josep Tabernero, Vice-Chairman WIN Consortium, Director VHIO and President ESMO.

*

** About WIN: WIN Consortium is a non-profit organization based in Paris, France. We are a worldwide network assembling cancer stakeholders from four continents to develop cutting edge concepts and clinical trials that improve survival for cancer patients. WIN members include 28 outstanding cancer centers plus 8 additional leading pharmaceutical, technology companies and patient advocacy organizations representing stakeholders in precision cancer medicine,

*** WINTHER received funding from the European Union Seventh Framework Program (FP7/2007-2013 under grant agreement n°306125), ARC Foundation for cancer research (France), Pfizer Oncology, Lilly France SAS, and Novartis Pharmaceuticals Corporation.Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

TAIPEI--( / )--GIGABYTE, a global leader in technology, joins MWC 2022 as the world’s bongacams 복권추첨기 most influential connectivity event takes spotlight from February 28th to March 3rd. The event creates opportunities for business leaders and trailblazers to network and share their thought leadership about the critical transformations shaping the industry and global economy in a 5G standardized era.

GIGABYTE expects to use its strength of rich product diversity and bongacams 연금복권분석 engineering expertise, bongacams 나눔복권 to demonstrate 상계9동포커 이서이 the scope of impact data center and embedded products have beyond improving the connectivity of telecommunications, which 라이브자스민 GIGABYTEup endless opportunities in a smart city.

GIGABYTE is an early adopter to design servers for Arm® architecture, the world’s most recognizable architecture for telecommunications, and is pleased to have two Arm 상계9동포커 server systems demo live at Arm’s booth at MWC including a network-in-a-box 5G solution and a solution compromised of an enterprise private network and a GPU. These demos are powered by the Ampere® Altra® cloud-native processors with massive core counts, and are available to the Arm ecosystem through the Arm 5G Solutions Lab, which is a place for hardware and software ecosystem partners can come together and demonstrate end-to-end solutions in a live test environment. The Arm-based 5G edge servers will exemplify future connectivity that has greater bongacams 스피또1000 speeds, lower latency, and is able to connect more devices.

As a partner of global automobile manufacturers, GIGABYTE specializes bongacams 실시간파워볼 in developing decision-making control units for different types of autonomous vehicles, as well as customized products such as ADAS ECUs, TCUs, assisting vehicle designers to develop their ideal products. The AI-enabled decision making bongacams 로또자동추첨기 control units will activate a traffic grid that’s smarter hence smoother and safer.

GIGABYTE brought its latest generation of embedded systems and developed Automated Guided Vehicle (AGV), which can be programmed to maneuver in designated routes, and Autonomous Mobile Robot (AMR), which can detect bongacams and avoid obstacles through bongacams 인터넷복권당첨 navigation to operate. The systems are designed to provide critical features such as low power consumption, high performance with rich I/O interface and high expansion flexibility, offering a bongacams 복권온라인구매 go-to choice to facilitate an automated environment for vital industries.

GIGABYTE’s 상계9동포커 스피또가격 recent project is a two-phase immersion cooling data center built for the prominent IC foundry giant that leads the world in advanced process bongacams 오메가카지노 technology. The project is aimed to not only prepare technology companies to combat the thermal dilemma bongacams associated with the ever-increasing CPU/GPU performance by providing a future-proof cooling solution, but also to set the industry standard for modern data centers bongacams 로또번호자동생성기 to effectively deliver better TCO, smaller carbon cartoonsex GIGABYTE’sand yield high(er) computing performance.

GIGABYTE continues its strong presence in digital format 상계9동포커 야동숲 on both MWC’s exhibitors’ page, which provides access to products bongacams info and downloadable PDFs, and its own [INUDSTRY] page, bongacams 로또발표 which offers an interactive bongacams 확인방법 3D overview of different industries envisioned in modern perspective with GIGABYTE’s comprehensive products and solutions.

GIGABYTE @ MWC 상계9동포커 로또당첨번호횟수 2022 bongacams 로또행운번호생성기 - bongacams 로또분석자료

INDUSTRY: bongacams 라인툰

Photos/Multimedia Gallery Available:GIGABYTE 상계9동포커 로또박스 Reimagines Connectivity With Servers and bongacams 로또리치번호 Embedded Systems bongacams 지지미한국 as MWC Returns to Barcelona